Bard Hernia Mesh Lawsuits: Claims, Settlements, and Who Qualifies to File
The Bard hernia mesh litigation is one of the largest medical device mass torts in U.S. history. Tens of thousands of patients have filed claims alleging that polypropylene hernia mesh products manufactured by C.R. Bard and its subsidiary Davol, Inc. caused serious complications including infection, organ perforation, mesh migration, and chronic pain. The vast majority of federal cases are consolidated in Multidistrict Litigation (MDL) 2846, pending in the Southern District of Ohio before Judge Edmund A. Sargus, Jr.
This guide explains the current status of the Bard hernia mesh litigation, the products involved, who may qualify to file a claim, projected settlement values, and how the broader landscape of mass tort lawsuits in the United States continues to evolve in 2026.
Overview of the Bard Hernia Mesh Litigation
Hernia mesh is a surgical implant used to reinforce weakened tissue during hernia repair. Surgeons rely on mesh because it can reduce the chance of recurrence compared with stitched-only repairs. Polypropylene became the dominant material because it is strong, lightweight, and inexpensive to produce. Bard and Davol manufactured a wide range of polypropylene and composite mesh devices that were implanted in patients across the United States.
The controversy stems from how Bard’s mesh products behave inside the human body. Plaintiffs allege that the polypropylene used in Bard’s hernia mesh shrinks, hardens, and triggers a chronic inflammatory response. Composite designs that combined polypropylene with a barrier layer were intended to prevent the mesh from sticking to internal organs, but plaintiffs claim the barrier degrades or fails, exposing tissue to the polypropylene and causing severe complications.
These complications—mesh migration, chronic pain, infection, bowel perforation, adhesions, and hernia recurrence—have led to thousands of revision surgeries and tens of thousands of lawsuits. Plaintiffs argue that Bard knew or should have known about the risks and either failed to adequately warn patients and surgeons or sold devices it knew to be defective.
What Is the Bard Hernia Mesh MDL?
MDL 2846, formally known as In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation, was created in 2018 to consolidate the rapidly growing volume of federal hernia mesh lawsuits. Multidistrict litigation is a procedural mechanism that allows federal cases sharing common questions of fact to be transferred to a single judge for coordinated pretrial proceedings.
MDLs are not class actions. Each plaintiff retains an individual lawsuit and the right to a personal recovery, but discovery, expert challenges, and procedural rulings are handled centrally. This structure is essential for efficiency in mass tort litigation because individually litigating tens of thousands of cases would be impossible.
MDL judges typically select a small group of cases for early bellwether trials. Bellwether verdicts give both sides information about how juries are likely to evaluate the evidence, which usually drives the parties toward a global settlement. The Bard MDL has followed this pattern: bellwether trials between 2021 and 2023 produced mixed results, but the cumulative pressure ultimately pushed Becton, Dickinson and Company (Bard’s parent) into negotiating a multi-billion dollar global resolution announced in October 2024.
Bard Mesh Products Named in Lawsuits
The Bard MDL master complaint references a wide range of polypropylene and composite mesh devices. The most frequently named products include:
- Composix Kugel Mesh — the device behind the original Class I FDA recall, designed with a memory recoil ring that was prone to breaking and causing bowel perforation
- Ventralex ST Mesh — a composite hernia patch with a polypropylene side and a barrier layer, alleged to cause adhesions, erosion, and chronic pain
- Ventralight ST Mesh — a similar composite device used in laparoscopic ventral hernia repair
- PerFix Plug Mesh — used in inguinal hernia repair, alleged to migrate and cause chronic groin pain and nerve damage
- 3DMax and 3DMax Light Mesh — pre-shaped polypropylene mesh used in inguinal repairs
- Bard Mesh, Bard Soft Mesh, and Sepramesh — additional polypropylene and composite products implicated in plaintiffs’ claims
Plaintiffs typically allege that these products were defectively designed, that Bard failed to adequately warn surgeons and patients, and that the company continued to market the devices despite mounting evidence of harm. The U.S. Food and Drug Administration cleared most of these products through the 510(k) pathway, which allows manufacturers to bypass full premarket testing by demonstrating substantial equivalence to an earlier device.
Common Hernia Mesh Complications Reported in Lawsuits
The injuries reported across the Bard hernia mesh litigation are serious, often life-altering, and frequently require multiple corrective surgeries. The complications most commonly alleged include:
- Infection at the implant site, sometimes recurring or chronic
- Mesh migration, in which the device shifts away from its original position
- Mesh erosion into surrounding tissues or organs
- Bowel perforation and bowel obstruction
- Adhesions between the mesh and internal organs
- Chronic abdominal or groin pain
- Hernia recurrence requiring repeat repair
- Fistulas, including enteric fistulas linking the bowel to other tissues
- Nerve damage and chronic neuropathic pain
Many of these injuries do not appear immediately. A patient may live with a Bard mesh implant for years before symptoms warrant medical investigation. When complications develop, treatment often requires explant surgery — a complex revision procedure that carries its own risks, particularly when the mesh has integrated with surrounding tissue or eroded into nearby organs.
Adverse event reports submitted to the FDA over two decades document the same pattern of complications described in the litigation. The agency has issued multiple safety communications regarding surgical mesh, and Bard’s Composix Kugel patch was the subject of a Class I recall — the most serious classification — beginning in December 2005 and expanding through January 2007.
Who Qualifies for a Bard Hernia Mesh Lawsuit?
Eligibility for a Bard hernia mesh claim generally depends on four core factors:
- A Bard or Davol-manufactured polypropylene hernia mesh device was implanted during your hernia repair surgery.
- You experienced complications connected to the mesh, such as infection, migration, perforation, chronic pain, or recurrence.
- You required additional medical treatment, including revision or explant surgery, hospitalization, or ongoing pain management.
- Your claim falls within the applicable statute of limitations, which varies by state and is often calculated from the date of discovery rather than the date of implant.
Documentation is critical. Settlement tier placement in MDL 2846 is heavily dependent on the strength of the medical record. Claimants with comprehensive operative reports, complication records, pathology results, and revision surgery documentation are positioned for higher-tier payouts. Claimants with incomplete records may be limited to substantially lower amounts. The records typically required to support a Bard hernia mesh claim include:
- Operative reports identifying the specific Bard mesh product implanted, ideally with the unique device identifier (UDI)
- Hospital and surgical records from the original hernia repair
- Records documenting the complications and the timeline of symptom development
- Imaging studies (CT, MRI, or X-ray) showing mesh failure, migration, or related findings
- Pathology reports from any explant or revision surgery
- Records of follow-up care, pain management, and any ongoing treatment
Because Bard’s mesh was implanted in patients across the country over a span of more than two decades, many claimants need records from multiple providers across different health systems. A review of active mass tort litigation can help patients understand whether their situation fits the eligibility criteria for a current claim.
Bard Hernia Mesh Settlement Estimates
In October 2024, Becton, Dickinson and Company announced a global settlement framework intended to resolve approximately 38,000 Bard hernia mesh claims. A Qualified Settlement Fund was established in early 2025, with funds held in escrow and administered by appointed special masters. Court-appointed Special Masters Ellen K. Reisman and John Jackson are overseeing the claims review and an Intensive Settlement Process scheduled to launch in January 2027 to resolve outstanding claims.
The settlement uses a tiered, points-based allocation system. Tier placement depends primarily on the severity of injury and the strength of the supporting medical documentation. Reported settlement parameters include:
- Quick-pay options of approximately $2,500 for less straightforward claims and $25,000 for straightforward claims with limited documentation
- Average projected payouts in the range of $60,000 to $70,000 for typical qualifying cases
- Higher-tier awards of $100,000 or more for claimants with comprehensive documentation of severe injuries, multiple revision surgeries, or permanent disability
Factors that influence individual payout amounts include the severity and permanence of the injury, the number of surgeries required, the extent of medical bills and lost wages, the strength of causation evidence, and the completeness of the medical record. Cases involving wrongful death, severe disability, or repeated revision surgeries generally command the highest awards.
Outside the global settlement, several individual verdicts have signaled the potential value of strong cases. In Trevino v. Davol/Bard, a Rhode Island state court jury returned a verdict of $4.8 million; the trial judge reduced the award by $250,000 in post-trial motions, leaving $4.55 million intact. Earlier rounds of Kugel mesh litigation, consolidated in MDL 1842, produced a $184 million settlement covering roughly 2,600 plaintiffs before that MDL closed in 2017.
Despite the global settlement, new Bard hernia mesh lawsuits continue to be filed in 2026, and approximately 23,693 cases remain pending in MDL 2846 as of April 2026. Plaintiffs who did not participate in the initial settlement, who developed complications later, or whose claims were filed after the settlement window may still pursue claims through the ongoing court-supervised process.
Timeline of the Bard Hernia Mesh Litigation
The Bard hernia mesh litigation has unfolded over more than two decades. Key milestones include:
- December 2005 – C.R. Bard issues a voluntary Class I recall of certain Composix Kugel Mesh patches after reports that the memory recoil ring could break and cause bowel perforation
- 2006–2007 – The Kugel recall is expanded multiple times to include additional product codes and lot numbers
- 2014 – The earlier Kugel mesh MDL (MDL 1842) reaches a $184 million settlement covering approximately 2,600 plaintiffs; that MDL closes in 2017
- 2018 – The Judicial Panel on Multidistrict Litigation creates MDL 2846 in the Southern District of Ohio to consolidate Bard polypropylene hernia mesh cases
- 2021–2023 – Bellwether trials produce mixed verdicts, including a defense verdict in the first bellwether and a $250,000 plaintiff verdict in the second
- 2023 – Trevino v. Davol/Bard yields a $4.8 million verdict in Rhode Island state court (reduced to $4.55 million in post-trial motions)
- October 2024 – Becton, Dickinson and Company announces a multi-billion dollar global settlement framework covering approximately 38,000 claims
- January 2025 – Qualified Settlement Fund established and claim review begins
- 2026 – Approximately 23,693 cases remain pending in MDL 2846; new claims continue to be filed
- January 2027 – Intensive Settlement Process scheduled to launch under court-appointed Special Masters; ISP timeline runs through June 2029
Patients and counsel can monitor official court filings through the MDL 2846 docket maintained by the Southern District of Ohio.
Other Major Hernia Mesh Mass Torts
Bard is not the only manufacturer facing hernia mesh litigation. Several parallel MDLs continue to move through the federal courts, each focused on a different defendant:
- Covidien (Medtronic) – MDL 3029 in the District of Massachusetts, with roughly 2,387 active cases as of April 2026 and bellwether trials in active development
- Atrium Medical Corporation – MDL 2753 in the District of New Hampshire, focused on the C-QUR mesh line, with approximately 217 cases remaining as the litigation winds down following confidential settlements
- Ethicon (Johnson & Johnson) – MDL 2782 in the Northern District of Georgia, focused on Physiomesh; most cases have been resolved, with only residual filings remaining
Multiple MDLs exist because each manufacturer designed its own mesh products, used different materials and barriers, and faces distinct factual and scientific allegations. Patients implanted with a non-Bard mesh device may still have a viable claim depending on the manufacturer and the nature of the complications. The broader landscape of emerging pharmaceutical and medical device lawsuits includes additional medical device investigations beyond hernia mesh.
How Mass Tort Lawsuits Work
Mass tort litigation differs from a traditional class action. In a class action, a class representative pursues claims on behalf of a large group, and any recovery is distributed across the class. In a mass tort, each plaintiff has an individual lawsuit, and settlements and verdicts are tailored to individual injuries rather than divided pro rata.
Most mass tort cases are handled on a contingency fee basis, meaning plaintiffs pay no upfront legal fees. The attorney is paid a percentage of any settlement or verdict, and clients owe nothing if there is no recovery. This structure is essential because most plaintiffs in medical device cases could not otherwise afford to pursue litigation against well-funded corporate defendants.
Bellwether trials are a defining feature of MDL practice. The court selects a representative group of cases to try first, and the resulting verdicts give both sides a sense of how juries view the evidence. Bellwether outcomes typically drive global settlement negotiations, with the parties agreeing on a tiered framework that allocates compensation based on injury severity, documentation, and other factors.
How to File a Bard Hernia Mesh Lawsuit
The process for filing a Bard hernia mesh claim generally follows these steps:
- Initial case evaluation. An attorney reviews the basic facts — when the mesh was implanted, what complications occurred, and whether revision surgery was required.
- Medical records collection. The legal team gathers operative reports, pathology results, imaging studies, and complication records, often spanning multiple providers and several years.
- Eligibility determination. Counsel evaluates whether the claim meets the qualifying criteria for MDL 2846 or a state court action and confirms compliance with the applicable statute of limitations.
- Case filing. The lawsuit is filed using the master complaint and short-form complaint procedures established in the MDL, or in an appropriate state court.
- MDL consolidation. Federal cases are transferred into MDL 2846 for coordinated pretrial proceedings.
- Settlement negotiation or trial. Most cases resolve through the global settlement framework or a structured tier review. Cases that do not resolve through settlement may proceed to individual trials.
Because each step requires careful documentation and adherence to court deadlines, patients are generally advised to consult experienced mass tort counsel as early as possible. Ongoing mass tort investigations continue to identify newly affected patients and emerging product liability issues across the medical device industry.
Frequently Asked Questions
What is the Bard hernia mesh lawsuit?
The Bard hernia mesh lawsuit refers to thousands of product liability claims filed against C.R. Bard, its subsidiary Davol, Inc., and parent company Becton, Dickinson and Company. Plaintiffs allege that Bard’s polypropylene hernia mesh devices were defectively designed and inadequately tested, causing complications such as infection, mesh migration, bowel perforation, adhesions, and chronic pain. Most federal cases are consolidated in MDL 2846 in the Southern District of Ohio. A global settlement framework announced in October 2024 covers approximately 38,000 claims, with payouts based on a tiered, points-based system.
Who qualifies for a Bard hernia mesh claim?
Patients generally qualify if they were implanted with a Bard or Davol polypropylene hernia mesh device, experienced complications such as infection, migration, perforation, or chronic pain, required additional medical treatment or revision surgery, and file within the applicable statute of limitations. Eligibility decisions ultimately depend on the specific medical history, the documented mesh device, the timeline of complications, and the law of the relevant jurisdiction. An attorney-led case review is the most reliable way to confirm eligibility, particularly because limitations periods vary substantially by state.
What complications are linked to Bard hernia mesh?
Complications reported across the litigation include infection, mesh migration, mesh erosion into surrounding tissues, bowel perforation and obstruction, adhesions, chronic abdominal or groin pain, hernia recurrence, fistulas, and nerve damage. Many patients require revision or explant surgery to address mesh failure. Symptoms may not appear for years after the original implant, which is one reason discovery-rule statutes of limitations often apply. The pattern of complications is consistent with FDA adverse event data and with allegations in the master complaint filed in MDL 2846.
What is the average settlement for a Bard hernia mesh lawsuit?
Settlement values vary significantly based on injury severity and documentation. Quick-pay options under the 2024 global settlement reportedly range from approximately $2,500 for less straightforward claims to $25,000 for straightforward claims. The average projected payout for typical qualifying cases is roughly $60,000 to $70,000. Higher-tier cases with comprehensive documentation of severe injuries, multiple surgeries, or permanent disability can reach $100,000 or more. Individual trial verdicts, such as the $4.55 million Trevino result, demonstrate the upper range when cases proceed outside the settlement framework.
How long does Bard hernia mesh litigation take?
Timelines vary depending on case type. Claims processed through quick-pay options under the global settlement may resolve within months. Standard tier evaluations generally take longer because they require complete medical records, lien resolution, and structured payout administration. Complex cases, including those involving severe injuries or unresolved Medicare and Medicaid liens, may take two to four years to fully resolve. The Intensive Settlement Process scheduled to launch in January 2027 is expected to handle outstanding claims through June 2029, indicating that some claimants may not see full distribution for several more years.
What evidence is needed for a Bard hernia mesh claim?
The most important evidence is the operative report from the original hernia repair, which identifies the specific mesh product implanted. Additional records include hospital and surgical records, complication and treatment records, diagnostic imaging showing mesh failure or migration, pathology reports from any explant surgery, and records of follow-up care. Documentation of lost wages, medical bills, and ongoing pain management strengthens the damages portion of the claim. Tier placement under the global settlement is heavily influenced by the completeness and quality of these records, making thorough documentation essential.
Is Bard settling hernia mesh lawsuits?
Yes. In October 2024, Becton, Dickinson and Company announced a global settlement framework covering approximately 38,000 hernia mesh claims, with a Qualified Settlement Fund established in early 2025. The settlement uses a tiered allocation model based on injury severity and documentation. Payments to qualifying claimants are being processed through court-appointed administrators, and an Intensive Settlement Process supervised by Special Masters Ellen K. Reisman and John Jackson is scheduled to launch in January 2027 to resolve remaining claims. Some plaintiffs have opted out, and litigation continues for cases outside the settlement framework.
Can you still file a Bard hernia mesh lawsuit?
Yes, in many cases. New Bard hernia mesh lawsuits continue to be filed in 2026, particularly by patients whose complications appeared after the initial settlement window or who were not previously aware of their potential claim. Eligibility depends on the implant date, the timing of complications, and the statute of limitations in the relevant state. Many states apply a discovery rule, meaning the limitations period begins when the patient knew or should have known about the injury, not on the date of the original implant. Prompt legal evaluation is recommended.
Speak With a Mass Tort Attorney About Your Bard Hernia Mesh Claim
If you or a loved one received a Bard or Davol hernia mesh implant and experienced complications such as chronic pain, infection, mesh migration, bowel perforation, or required revision surgery, you may be eligible to file a claim under the ongoing MDL 2846 settlement framework or through state court litigation.
CredibleLaw connects patients with experienced mass tort attorneys handling Bard hernia mesh claims and a wide range of other active mass tort lawsuits. Case evaluations are confidential and free, and most mass tort claims are handled on a contingency fee basis — meaning no fee unless your case results in a recovery.
The Intensive Settlement Process launching in January 2027 will set the framework for resolving remaining hernia mesh claims, but documentation deadlines and statutes of limitations apply now. Patients who suspect their hernia mesh may have failed should request their operative reports and consult counsel without delay.
